Skip to main content
Premium Trial:

Request an Annual Quote

Millipore, Serologicals, CST, Bio-Rad, Cyntellect, Sigma-Aldrich

Premium

Millipore to Sell $550M in New Notes to Help Fund Serologicals Acquisition

Millipore said this week that it plans to raise $550 million in convertible senior notes to finance its acquisition of Serologicals.

The notes, due 2026, will be offered to institutional buyers.

Millipore said in April that it would acquire Serologicals for $1.4 billion in cash. Millipore said it will use a portion of its latest fundraising round to pay for a portion of the acquisition.

Initial purchasers will receive a 13-day option to buy up to an additional $82.5 million of the convertible notes. Holders would receive a cash payment up to the principal amount of the note and Millipore common stock equivalent to the note's conversion value in excess of the principal amount for each note.

Any remaining funds will be added to the company's working capital and will be used for general corporate purposes, the company said.


CST, Bio-Rad to Develop Phosphoprotein Assays for Signal Transduction Research

Cell Signaling Technology said this week that it has partnered with Bio-Rad Laboratories to develop phosphoprotein assays to be commercialized with Bio-Rad's bead-based assays.

Under the partnership, CST will develop antibodies for kinase activation and protein phosphorylation assays to be used in Bio-Rad's multiplex bead-based assays for the Bio-Plex suspension array system.

CST will develop a broader array of antibodies for the Bio-Plex platform. Bio-Rad's phosphoprotein assays are optimized to simultaneously assess kinase and signaling protein activation states and provide critical tools for disease research and drug development.

Financial details were not disclosed.


Cyntellect Receives $2.2M Milestone Payment from Sigma-Aldrich

Cyntellect said this week that it has received an equity purchase milestone payment worth $2.2 million from Sigma-Aldrich for satisfying certain terms and conditions under the companies' exclusive Cell Xpress service commercialization agreement started one year ago.

Specifically, Sigma-Aldrich will use Cyntelletc's LEAP platform to support its Cell Xpress service business to identify and clone high-producing cells for the manufacture of biopharmaceuticals and diagnostic antibodies.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.